Eidos Therapeutics Inc
(EIDX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -8,876 | -11,941 | -6,830 | -4,057 | -2,342 |
| Depreciation Amortization | 1,021 | 4 | 2 | 1 | N/A |
| Accounts payable and accrued liabilities | 1,102 | 472 | 888 | 344 | 364 |
| Other Working Capital | 1,713 | 1,142 | 644 | 719 | 560 |
| Other Operating Activity | -851 | 606 | -862 | -344 | -401 |
| Operating Cash Flow | $-5,891 | $-9,717 | $-6,158 | $-3,337 | $-1,819 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -114 | -53 | -6 | -3 | -3 |
| Investing Cash Flow | $-114 | $-53 | $-6 | $-3 | $-3 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 10,000 | N/A | 0 | N/A | N/A |
| Common Stock Issued | 89 | 318 | 15 | 13 | 6 |
| Other Financing Activity | 15,688 | 12,993 | 12,993 | 3,998 | 4,000 |
| Financing Cash Flow | $25,777 | $13,311 | $13,008 | $4,011 | $4,006 |
| Beginning Cash Position | 5,497 | 1,956 | 1,956 | 1,956 | 1,956 |
| End Cash Position | 25,269 | 5,497 | 8,800 | 2,627 | 4,140 |
| Net Cash Flow | $19,772 | $3,541 | $6,844 | $671 | $2,184 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,891 | -9,717 | -6,158 | -3,337 | -1,819 |
| Capital Expenditure | -114 | -53 | -6 | -3 | -3 |
| Free Cash Flow | -6,005 | -9,770 | -6,164 | -3,340 | -1,822 |